Gratwohl A, Schmid O, Baldomero H, Horisberger B, Urbano-Ispizua A
Department of Internal Medicine, Division of Hematology, Kantonsspital Basel, Basel, Switzerland.
Bone Marrow Transplant. 2004 Nov;34(10):855-75. doi: 10.1038/sj.bmt.1704653.
This 2002 European Group for Blood and Marrow Transplantation (EBMT) activity survey concentrates on current status, increase and decrease in haematopoietic stem cell transplantation (HSCT) activity in Europe and investigates the association of transplant rates with team density. In 2002, there were 20 207 HSCT, 6915 allogeneic (34%), 13 292 autologous (66%) and 3947 additional re- or multiple transplants collected from 586 centres in 39 European countries. Main indications were leukaemias (6523 (32%; 76% allogeneic)); lymphomas (10 760 (53%; 92% autologous)); solid tumours (1913 (9%; 92% autologous)) and nonmalignant disorders (874 (4%; 92% allogeneic)). Compared to 2001, there were increases (>10%) for AML, ALL 1st CR, CML not 1st cP, MDS, SAA and CLL in allogeneic HSCT and for MDS, Ewing's sarcoma, soft-tissue sarcoma and ovarian cancer in autologous HSCT. Decreases (>10%) were observed in autologous HSCT for acute leukaemias beyond 1st CR, CML cP, glioma, breast cancer and lung cancer. Correlation of transplant rates (number of transplants per 10 million inhabitants) with team density (number of transplant teams per 10 million inhabitants) suggests different diffusion patterns for autologous compared to allogeneic HSCT. These data describe current practice for blood and marrow transplantation in Europe and give some hints about mechanisms involved in HSCT rates.
这项2002年欧洲血液与骨髓移植组（EBMT）的活动调查聚焦于欧洲造血干细胞移植（HSCT）活动的现状、增减情况，并研究移植率与团队密度之间的关联。2002年，从39个欧洲国家的586个中心收集到20207例HSCT，其中6915例为异基因移植（34%），13292例为自体移植（66%），另有3947例再次或多次移植。主要适应证为白血病（6523例（32%；异基因移植占76%））、淋巴瘤（10760例（53%；自体移植占92%））、实体瘤（1913例（9%；自体移植占92%））和非恶性疾病（874例（4%；异基因移植占92%））。与2001年相比，异基因HSCT中急性髓系白血病（AML）、急性淋巴细胞白血病（ALL）首次完全缓解（CR）、慢性髓性白血病（CML）非首次慢性期（cP）、骨髓增生异常综合征（MDS）、重型再生障碍性贫血（SAA）和慢性淋巴细胞白血病（CLL）的移植例数增加（>10%），自体HSCT中MDS、尤因肉瘤、软组织肉瘤和卵巢癌的移植例数增加。自体HSCT中首次CR后急性白血病、CML慢性期、神经胶质瘤、乳腺癌和肺癌的移植例数减少（ >10%）。移植率（每1000万居民的移植例数）与团队密度（每1000万居民的移植团队数）的相关性表明，自体HSCT与异基因HSCT的扩散模式不同。这些数据描述了欧洲血液与骨髓移植的当前实践，并对HSCT率相关机制给出了一些提示。
